Osteopenia: Debates and Dilemmas

被引：14
|
作者：
Zhang, Jie [1 ]
Morgan, Sarah L. [2 ]
Saag, Kenneth G. [2 ]
机构：
[1] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA
来源：
CURRENT RHEUMATOLOGY REPORTS | 2013年 / 15卷 / 12期
关键词：
Osteopenia; Pharmacologic treatment; Debates; Epidemiology; Fracture risk; FRAX; Adverse events; BONE-MINERAL DENSITY; ESTROGEN PLUS PROGESTIN; OLDER US ADULTS; POSTMENOPAUSAL WOMEN; PHARMACOLOGICAL-TREATMENT; DOUBLE-BLIND; OSTEOPOROSIS; FRACTURE; RISK; INTERVENTION;
D O I：
10.1007/s11926-013-0384-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Whether or not to use pharmacologic agents for primary prevention of fracture among elderly men and women with osteopenia is debated by clinicians. In this review we provide an update to enable better understanding and characterization of this population, including the prevalence of osteopenia, transitioning from osteopenia to osteoporosis, and clinically applicable tools for fracture risk assessment. We also emphasize the very limited evidence of the benefits and risks of anti-osteoporotic agents for this population for primary fracture prevention, and the need for future studies to guide clinical practice.
引用
收藏
页数：5
相关论文
共 50 条
12345